返回 
加入收藏
美托洛尔联合参松养心胶囊治疗室性早搏的临床观察
x
请在关注微信后，向客服人员索取文件
| 篇名： | 美托洛尔联合参松养心胶囊治疗室性早搏的临床观察 |
| TITLE： | |
| 摘要： | 目的：观察美托洛尔联合参松养心胶囊治疗室性早搏的疗效和安全性。方法：回顾性分析2016年1月－2017年1月收治的104例室性早搏患者资料，按用药方案的不同分为对照组（52例）和观察组（52例）。对照组患者给予酒石酸美托洛尔片25 mg，口服，每日3次；观察组患者在对照组治疗的基础上给予参松养心胶囊1.2 g，口服，每日3次。两组均连续治疗28 d。观察两组患者的临床疗效，治疗前后心电图P-R间期、Q-T间期、24 h早搏次数、心率、心悸发生情况及不良反应发生情况。结果：观察组患者总有效率（92.30％）显著高于对照组（76.92％），差异有统计学意义（P＜0.05）。治疗前，两组患者心电图P-R间期、Q-T间期、24 h早搏次数、心率、心悸次数比较，差异均无统计学意义（P＞0.05）。治疗后，两组患者心电图P-R间期、Q-T间期均显著高于同组治疗前，且观察组显著高于对照组；两组患者24 h早搏次数、心悸次数及对照组患者心率均显著低于同组治疗前，且观察组24 h早搏次数、心悸次数显著低于对照组，差异均有统计学意义（P＜0.05）；观察组患者治疗前后心率比较，差异无统计学意义（P＞0.05）。两组患者不良反应总发生率比较，差异无统计学意义（P＞0.05）。结论：美托洛尔联合参松养心胶囊治疗室性早搏疗效显著，可减少早搏次数，且未增加不良反应的发生。 |
| ABSTRACT： | OBJECTIVE： To observe therapeutic efficacy and safety of metoprolol combined with Shensong yangxin capsule in the treatment of ventricular premature beat. METHODS： A total of 104 patients with ventricular premature beat during Jan. 2016-Jan. 2017 were analyzed retrospectively， and they were divided into control group （52 cases） and observation group （52 cases） according to medication plan. Control group was given Metoprolol tartrate tablet 25 mg orally， 3 times a day. Observation group was given Shensong yangxin capsule 1.2 g orally， 3 times a day， on the basis of control group. Both groups were treated for consecutive 28 d. Clinical efficacies of 2 groups were observed. The electrocardiogram P-R interval and Q-T interval， 24 h premature beat times， heart rate， the occurrence of palpitation before and after treatment and ADR were observed. RESULTS： Total response rate of observation group （92.30％） was significantly higher than that of control group （76.92％）， with statistical significance （P＜0.05）. Before treatment， there was no statistical significance in electrocardiogram P-R interval and Q-T interval， 24 h premature beat times， heart rate or palpitation times between 2 groups （P＞0.05）. After treatment， electrocardiogram P-R interval and Q-T interval of 2 groups were significantly higher than before treatment， and the observation group was significantly higher than the control group. 24 h premature beat times， palpitation times of 2 groups and heart rate of control group were significantly lower than before treatment； and 24 h premature beat times， palpitation times of the observation group was significantly lower than the control group， with statistical significance （P＜0.05）； there was no statistical significance in heart rate of observation group before and after treatment （P＞0.05）. There was no statistical significance in the total incidence of ADR between 2 groups （P＞0.05）. CONCLUSIONS： For ventricular premature beat， metoprolol combined with Shensong yangxin capsule show significant therapeutic efficacy， can reduce the times of premature beat and improve patients’electrocardiogram without increasing the occurrence of ADR. |
| 期刊： | 2018年第29卷第6期 |
| 作者： | 杨苓，张敏，官计，龙霖，刘利 |
| AUTHORS： | YANG Ling，ZHANG Min，GUAN Ji，LONG Lin，LIU Li |
| 关键字： | 美托洛尔；参松养心胶囊；室性早搏；疗效；安全性 |
| KEYWORDS： | Metoprolol； Shensong yangxin capsule； Ventricular premature beat； Therapeutic efficacy； Safety |
| 阅读数： | 1015 次 |
| 本月下载数： | 4 次 |
* 注：未经本站明确许可，任何网站不得非法盗链资源下载连接及抄袭本站原创内容资源!在此感谢您的支持与合作！
